Enjoy complimentary customisation on priority with our Enterprise License!
The inflammatory bowel disease market size is estimated to grow by USD 7.68 billion at a CAGR of 5.77% between 2023 and 2027. The increasing incidence of IBD worldwide is leading to a greater demand for effective therapies to manage the condition. The growing preference for biologics and targeted therapies, which offer more personalized treatment options with potentially fewer side effects, is driving market growth. Additionally, increasing awareness of IBD, its symptoms, and available treatments is leading to earlier diagnosis and treatment, further driving market demand. Furthermore, advancements in biological therapies and targeted treatments are expanding the treatment options available for IBD patients, driving market growth. The emphasis on improving the quality of life for IBD patients and reducing the burden of the disease is also fueling research and development efforts in the field, leading to innovative therapies and treatment approaches.
To learn more about this report, View Report Sample
This market report extensively covers market segmentation by distribution channel (offline and online), type (Crohn's disease and ulcerative colitis), and geography (North America, Europe, Asia, and Rest of the World). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
The market share growth by the offline segment will be significant during the forecast period. The offline channel is a crucial element in the global IBD market. This segment comprises the distribution of IBD therapeutics through traditional brick-and-mortar pharmacies and drugstores. Although the global IBD market has seen an increase in penetration of Internet distribution channels, due to their easy availability and ease of use, there is still a considerable influence on the market from offline channels.
Get a glance at the market contribution of various segments View the PDF Sample
The offline segment showed a gradual increase in the market share of USD 16.67 billion in 2017. Consumers often prefer to purchase drugs in brick-and-mortar stores due to the assurance of immediate availability and face-to-face interactions with pharmacists. The offline channel benefits from this preference, as it allows both established and emerging pharmaceutical companies to reach a wider consumer base.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The increasing incidence and prevalence of chronic gastrointestinal diseases and growing healthcare expenditure are driving the growth of the market in North America. Furthermore, factors such as the growing focus of pharmaceutical and biotechnology companies on R&D to develop novel drugs for IBD and the presence of global and regional companies are also driving the market growth in the region during the forecast period.
The market is witnessing significant advancements, with a focus on innovative therapies and enhanced diagnostic approaches. Key players like Allergan, Ferring Pharmaceuticals, and Lilly are investing in research and development to develop biological drugs and JAK inhibitors such as Cimzia and Jyseleca. These advancements aim to address the complex nature of IBD, including Crohn's disease, through targeted therapies. Additionally, collaborations with organizations like the Crohn's & Colitis Foundation of America are driving clinical trials and providing better insights into the environmental triggers and genetic predispositions of IBD, benefiting healthcare systems and professionals globally. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing demand for biologics and targeted therapies is notably driving the market growth. Surgery is often used to alleviate symptoms in patients with ulcerative colitis and Crohn's disease. However, individuals with Crohn's disease are at a higher risk of developing colon cancer, so surgical techniques may also be employed to reduce this risk. Gastrointestinal surgeries for IBD can carry risks, which can be a concern for patients considering their treatment options. Advances in surgical techniques and medications like biological drugs such as Cimzia have helped improve outcomes and reduce risks, but patients need to discuss all potential risks and benefits with their healthcare providers. Clinical trials and research efforts, supported by organizations like the Crohn's & Colitis Foundation of America, play a crucial role in advancing our understanding and treatment of Crohn's disease and ulcerative colitis. Additionally, companies like Allergan and CytoReason are involved in developing innovative solutions for IBD.
Due to the potential side effects and risks of surgery, pharmaceutical and biopharmaceutical companies are focusing on developing biologics and advanced targeted therapies for gastrointestinal diseases like IBD. These therapies target specific proteins, tissues, or genes responsible for gastrointestinal diseases. The shift towards using biologics and biosimilars as alternatives to traditional IBD therapies is expected to drive the growth of the global market in the forecast period.
The new launches of IBD therapeutics are a primary trend in the inflammatory bowel disease market. companies in the market are focusing on the development of new therapeutics, such as small molecules and biologics, for the treatment of various IBDs. The development of advanced treatments for inflammatory bowel disease has been supported by increasing research and development spending from pharmaceutical and biopharma companies, as well as new product launches.
HUMIRA is the first subcutaneous biologic therapeutic option for patients with moderately to severely active ulcerative colitis aged five and above. Adalimumab-flip, a TNF inhibitor, was given the all-clear by the US FDA in July 2020 to be used in the treatment of adult patients with mildly to moderately active Crohn's disease or ulcerative colitis who have not responded well to traditional therapy. Such developments and an increase in the number of new launches and product approvals of therapeutics for IBD are expected to drive the growth of the global IBD market during the forecast period.
The adverse effects associated with drugs used for treating IBD is a major challenge in the market. Corticosteroids are one of the most commonly prescribed medications for Crohn's disease and ulcerative colitis. Although corticosteroids are used to reduce inflammation in the digestive tract, they should not be used in the long term. Steroids interfere with the formation of a protective mucous layer inside the stomach.
Moreover, factors such as the nature of the medicine, its content, and duration of use are crucial to the side effects of IBD therapies. In general, it is very easy to treat side effects resulting from the use of these medicines as they often last only a few days. However, the increased chances of developing adverse reactions due to the long-term intake of certain IBD therapeutics may reduce the adoption of such products, which will hamper the growth of the global IBD market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AstraZeneca - The company offers inflammatory bowel disease solutions such as CAR-T therapy.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
The market is driven by advancements in diagnostic techniques and therapeutic drugs, offering enhanced options for patients. The disease burden of IBD, particularly the Crohn's disease segment, underscores the need for improved access to healthcare systems and services. Biologic drugs like Remicade, Entyvio, Simponi, and Skyrizi target the immune system disruption characteristic of IBD, providing relief for patients. Emerging treatments such as IL inhibitors, Janus kinase inhibitors, and toll-like receptor agonists offer further hope for managing the disease. With technological advancements and the rise of telemedicine, healthcare professionals can now better manage IBD, ensuring timely diagnosis and treatment.
The market has seen significant advancements in diagnostic and therapeutic drugs, leading to improved disease detection rates and enhanced therapy. Understanding the disease pathophysiology has been key in developing targeted treatments, with drugs categorized under various Drug Classes such as TNF inhibitors like Remicade and Humira. Emerging treatments like Lilly's Mirikizumab and Takeda's Rinvoq offer new options for patients. The availability of these drugs through different Routes of Administration, including injectable and oral, has made them more accessible through various healthcare channels such as hospital pharmacies, online pharmacies, and retail pharmacies. This has significantly improved the quality of care for IBD patients, particularly in industrialized countries.
Market Scope |
|
Report Coverage |
Details |
Page number |
165 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.77% |
Market growth 2023-2027 |
USD 7.68 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
4.92 |
Regional analysis |
North America, Europe, Asia, and Rest of the World (ROW) |
Performing market contribution |
North America at 38% |
Key countries |
US, Canada, UK, China, and India |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, AbbVie Inc., AstraZeneca, Aurobindo Pharma Ltd., Bausch Health Co. Inc., Baxter International Inc., Bayer AG, Biocon Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson and Johnson Services Inc. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.